---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-000924"
form_type: "8-K"
ticker: "NUWE"
cik: "0001506492"
company_name: "Nuwellis, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:45:10.783675+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nuwellis reports preliminary Q4 revenue of $2.3M, up 42% YoY; FY22 revenue $8.5M, up 8%

## Summary
- Preliminary Q4 2022 revenue $2.3M, up 42% YoY; full-year 2022 revenue $8.5M, up 8% YoY.
- Pediatrics segment grew 92% YoY; Heart Failure +47%; Critical Care +24%.
- Growth driven by commercial team expansion and market penetration beyond heart failure.
- CEO cites strong sales momentum and commitment to making Aquadex SmartFlow standard of care.

## SEC filing metadata
- accession: 0001140361-23-000924
- form_type: 8-K
- ticker: NUWE
- cik: 0001506492
- company_name: Nuwellis, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506492/000114036123000924/0001140361-23-000924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506492/000114036123000924/brhc10046422_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-000924
- JSON: https://secwatch.observer/filing/0001140361-23-000924.json
- Plain text: https://secwatch.observer/filing/0001140361-23-000924.txt

## Key facts
- Earnings Releases
  Nuwellis, Inc. reported the fourth quarter and full year 2022 results: revenue approximately $2.3 million and $8.5 million.
  - Period: the fourth quarter and full year 2022
  - Revenue: approximately $2.3 million and $8.5 million
  - Result: preliminary results
  source text: preliminary unaudited results for fourth quarter and full year 2022. Preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be approximately $2.3 million and $8.5 million, respectively, representing an increase of 42% and 8% over the same periods last year. The fourth quarter growth rate reflects benefits from the Company’s
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506492/000114036123000924/0001140361-23-000924-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.